Citation Impact
Citing Papers
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
2009 Standout
Osteoporosis
2019 Standout
Targeting Interleukin-6 Signaling in Clinic
2019
The role of JAK/STAT signaling pathway and its inhibitors in diseases
2020
Rheumatoid arthritis
2018 Standout
Rheumatoid arthritis
2016 Standout
Synovial Tissue Inflammation Mediated by Autoimmune T Cells
2019 StandoutNobel
A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro
2017
Kinase inhibition in autoimmunity and inflammation
2020
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
2017
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
2017
The emerging safety profile of JAK inhibitors in rheumatic disease
2017
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
2018
PTPN2 links colonic and joint inflammation in experimental autoimmune arthritis
2020 StandoutNobel
Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
2020
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
2020
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
2018
Hidradenitis suppurativa
2020 Standout
Ulcerative colitis
2020 Standout
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
2018
Biological Therapies of Immunologic Diseases
2017
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Dispensable roles of Gsdmd and Ripk3 in sustaining IL-1β production and chronic inflammation in Th17-mediated autoimmune arthritis
2021 StandoutNobel
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
2019
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis
2021
The safety of baricitinib in patients with rheumatoid arthritis
2020
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
2017
Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
2020
Overview of pharmacological activities ofAndrographis paniculataand its major compound andrographolide
2018 Standout
Cytokine Storm
2020 Standout
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
2018
Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
2008
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
2020
Etanercept for the Treatment of Rheumatoid Arthritis
2018
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
2020
Control of foreign Ag‐specific Ab responses by Treg and Tfr
2020 StandoutNobel
Selective JAK inhibitors in development for rheumatoid arthritis
2014
Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis
2018
Impaired T cell receptor signaling and development of T cell–mediated autoimmune arthritis
2020 StandoutNobel
Industry sponsorship and research outcome
2017 Standout
Works of C. Gaich being referenced
Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study
2015
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
2016
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
2016
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
2017
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
2019
Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA
2019
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass
2006
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
2017
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK ) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis
2016
Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis
2016
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
2017
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
2019
LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis
2012